Association of missense polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or abiraterone
Importance Recently, genetic polymorphism inHSD3B1encoding 3β-hydroxysteroid
dehydrogenase-1 has been shown to be associated with oncological outcome when treated
with androgen-deprivation therapy (ADT) for prostate cancer. Upfront abiraterone combined
with ADT has proved survival benefit. However, its effect on oncological outcome among
different ethnicities and in abiraterone treatment remain unclear. Objective To investigate the
significance of missense polymorphism inHSD3B1gene among men treated with primary …
dehydrogenase-1 has been shown to be associated with oncological outcome when treated
with androgen-deprivation therapy (ADT) for prostate cancer. Upfront abiraterone combined
with ADT has proved survival benefit. However, its effect on oncological outcome among
different ethnicities and in abiraterone treatment remain unclear. Objective To investigate the
significance of missense polymorphism inHSD3B1gene among men treated with primary …
